Oppenheimer Maintains Outperform on Amrize, Lowers Price Target to $52

Benzinga · 2d ago
Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $55 to $52.